Oncology treatment decision-making has always been complex, and this has been amplified year on year as the market expands at an unprecedented rate.
The arrival of immunotherapies has significantly altered the therapeutic landscape, leading to the first approvals for tumour-agnostic drugs and widening the range of potential oncology treatments to a previously unseen level.
As drugs in development increasingly focus on personalized treatment, the market is further challenged to achieve the ever-present need to balance between treatment efficacy and tolerability, while also considering the increased financial toxicity that these new offerings may create.
Our oncology evidence provides insight and understanding of the real-world impact of new drugs on treatment patterns, highlighting the healthcare resource utilization of oncology patients at an individual tumour and treatment level.
Autoimmune 
CNS / Pain 
Other Conditions 
CV / Metabolic 
Rare Diseases 
Respiratory Disease